The Cultural, Religious and Linguistic (CRL) Rights Commission recently retracted its report on the KwaSizabantu Christian Mission, where it was investigating violations of religious freedoms. The ...

Corcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce ...

The Commission for the Promotion and Protection of the Rights of Cultural, Religious and Linguistic Communities (CRL Rights Commission) on Friday held a briefing with the Christian sector on ...

Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 6.1% in the afternoon session after the company provided an encouraging business update at an investor conference, ...

Madison Investments, an investment advisor, released its “Madison Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The third quarter was difficult for ...

Watch Mohamed Light prove why he’s called the GOAT in the CRL World Finals 2025 as he dominates the Clash Royale arena with unmatched skill and strategy #ClashRoyale #MohamedLight #CRL2025 #Esports ...

In September, the Food and Drug Administration released its recent complete response letter (CRL) to Lykos Therapeutics, denying approval for MDMA-assisted therapy for post-traumatic stress disorder.

Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies, which founded Lykos, bemoaned a “moving of the goal posts” in Lykos’ rejection but looked for positives in the ...

On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for ...

According to the CRL, the STARGLO study did not provide enough evidence to support the proposed second line DLBCL indication in the US patient population. The Food and Drug Administration (FDA) has ...